Company* |
Company | Type/Product Area | Terms/Details (Date) |
| | |||
Diversa Corp. |
Cargill Health and Food Technologies |
Collaboration to develop enzymes for the cost-effective production of an undisclosed product |
Diversa gets up-front payments and research funding, and is entitled to milestone payments, license fees and royalties on resulting products (4/11) |
Geneva |
Current Science Group (UK) |
They formed a joint venture company named Current BioData Ltd. |
The new company will focus on the further development and marketing of GeneBio's ProXenter discovery platform (3/3) |
Senomyx |
Nestle SA (Switzerland) |
They extended for three years a deal to discover novel flavors and flavor enhancers in the dehydrated and culinary food and frozen food fields |
The initial three-year deal was signed in 2002; Senomyx will get funding of up to $6.6M in the extension, and would get royalties on any resulting sales (4/20) |
Vion |
B&P Co. Inc. |
B&P got nonexclusive rights to use Vion's Melasyn technology |
B&P plans to develop cosmetic products incorporating Melasyn, a synthetic form of melanin; Vion would get royalties on sales in countries where it has patents (4/15) |
Xenogen Corp. |
MIR Preclinical Services |
MIR purchased and sub- licensed Xenogen's biophotonic imaging technologies |
The contract research organization got rights to use the technology in preclinical research except in infectious diseases (4/12) |
| | |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
